Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab.

ABSTRACT:

Background and purpose

Clinical tools to optimally select real-world metastatic renal cell carcinoma (mRCC) patients for treatment with ipilimumab-nivolumab remain to be identified.

Patient and methods

Medical records of the first 100 mRCC patients treated with ipilimumab-nivolumab at three Swedish centers were retrospectively analyzed. Data on International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk, baseline levels of routine blood markers, and tumor burden were collected. Outcome variables were progression-free survival (PFS), overall survival (OS), and radiological response (RR) according to clinical routine imaging.

Results

At a median follow-up of 22 months, 65% had progressed or died with a median PFS of 7 months and an estimated median OS

SUBMITTER: Kheir A 

PROVIDER: S-EPMC12509422 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature